Changes in Beneficial Ownership · 4
Mineralys Therapeutics, Inc.
MLYSNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1790978009.xml
Filing details
- Report period
- 2026-09-30
- Issuer
- Mineralys Therapeutics, Inc.
- Issuer CIK
- 0001933414
- Trading symbol
- MLYS
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Congleton Jon
- Reporting owner CIK
- 0001644975
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- 150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR, PA, 19087
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-30 | S · Form 4[F1] | 75,000 | D | 25.4622[F2] | 528,621 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025.↩ 1
- F2
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.0000 to $25.8201. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
Signature 1
- Signed
- /s/ Adam Levy, Attorney-in-fact
- Date
- 2026-10-02
Company context
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.